Calico(CRC)
Focus: Calico is a publicly-traded biotechnology company focused on aging treatments and related therapeutic areas including oncology, cardiovascular disease, and infectious diseases. The company generated $2.8B in revenue in FY2025 with $564M net income, operating as a well-capitalized biotech player.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
19
Should You Work at Calico?
AI assessmentCalico offers financial stability and exposure to aging biology research, but career growth depends on whether early-stage bets translate to clinical validation.
Why Work Here
- Strong financial performance with $2.8B revenue and $564M net income in FY2025 provides stability and investment in R&D
- Growing pipeline with 22 active programs, including promising early-stage oncology and neurology candidates like Fosigotifator (awarded FDA Breakthrough Therapy Designation for Vanishing White Matter Disease in 2026)
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$2.8B
Pipeline & Clinical Trials
DRUG: ABBV-CLS-484
Advanced Solid Tumor CancerClinical Trials (1)
NCT06188975Expanded Access to ABBV-CLS-484
N/AHelp build intelligence for Calico
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.